论文部分内容阅读
目的评价术前化疗对生存率的影响。方法在Pubmed、Science direct、CNKI、CBM、万方等数据库,收集已公开发表的比较术前化疗加手术治疗和直接手术治疗对Ⅲ期非小细胞癌(NSCLC)患者的临床随机对照研究,对检索到的原始研究的质量进行评估。对符合条件的所有研究结果进行Meta分析。结果符合纳入标准的文章共12篇,总样本量2320例,术前化疗共1154例,而直接手术1146例。分析结果显示新辅助化疗后手术治疗与直接手术治疗相比,死亡风险优势比OR=0.63,95%CI(0.52,0.75),差异有统计学意义(P<0.05)。结论分析表明术前化疗对改善NSCLC患者的5年生存率有明显益处。
Objective To evaluate the effect of preoperative chemotherapy on the survival rate. Methods A randomized controlled clinical trial was conducted in PubMed, Science direct, CNKI, CBM and Wanfang databases to compare the published preoperative chemotherapy plus surgical treatment and direct surgical treatment in patients with stage Ⅲ non-small cell carcinoma (NSCLC) The quality of the original study retrieved was evaluated. Meta-analysis was performed on all eligible studies. Results A total of 12 articles meeting the inclusion criteria were included, with a total sample size of 2320 cases. There were 1154 cases of preoperative chemotherapy and 1146 cases of direct surgery. The analysis showed that the odds ratio of death risk after neoadjuvant chemotherapy was 0.63 and 95% CI (0.52, 0.75), respectively. The difference was statistically significant (P <0.05). Conclusions The analysis shows that preoperative chemotherapy has obvious benefits in improving the 5-year survival rate of patients with NSCLC.